# A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy

> **NCT07069270** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fujian Cancer Hospital** · enrollment: 28 (estimated)

## Conditions studied

- Vunakizumab
- Adebrelimab
- Small Cell Lung Cancer

## Interventions

- **DRUG:** Vunakizumab (IL-17A inhibitor)
- **DRUG:** Adebrelimab
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT07069270
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2026-06-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07069270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07069270, "A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07069270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*